Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tobi Podhaler

- PMLiVE

NICE refuses to back Zaltrap as Sanofi exhausts its options

Patient access scheme and appeal fail to overcome cost concerns

National Institute for Health and Care Excellence NICE logo

Mixed cancer news from NICE

Agency backs Janssen’s myeloma drug but denies Bayer’s Xofigo in prostate cancer

National Institute for Health and Care Excellence NICE logo

Boehringer cancer drug on course for NHS use in UK

NICE backs Giotrif in draft guidance

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

National Institute for Health and Care Excellence NICE logo

NICE denies pharma influence on statin guidance

Responds to accusations committee members were ‘in the pay’ of drug firms

- PMLiVE

Pfizer still number one – just

The PMLiVE Top Pharma List is updated with a ranking of the 25 biggest companies in the industry

- PMLiVE

No price ceiling for rare disease drugs, say MPs

BIA survey comes ahead of consultation on evaluation framework for ultra-orphans

- PMLiVE

AZ launches combination diabetes drug in UK

Xigduo combines Forxiga and metformin

- PMLiVE

New data puts Jakafi on course for blockbuster status

Novartis/Incyte drug meets targets in blood cancer trial

NICE and ‘ultra orphans’

NICE and its processes for ‘highly specialised therapies’

Novartis building

Novartis’ dermatology plans advance with Xolair approval

Green light for use in chronic spontaneous urticaria

- PMLiVE

NICE relents and backs Pfizer’s Inlyta

Recommends drug to treat advanced kidney cancer on NHS in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links